VCEL Q3 2023 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena

VCELVericel Corporation

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$46M+18.2% YoY

Gross Profit

$31M67.2% margin

Operating Income

-$5M-11.1% margin

Net Income

-$4M-8.0% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

-0.7%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

$600,000

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$318M

Total Liabilities

$114M

Stockholders' Equity

$204M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$39M	+18.2%
Gross Profit	$31M	$25M	+21.3%
Operating Income	-$5M	-$7M	+25.5%
Net Income	-$4M	-$7M	+44.4%

Revenue Segments

MACI Implants And Kits

$38M100%